BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int 2015;2015:917968. [PMID: 25879040 DOI: 10.1155/2015/917968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kotzerke J, Buesser D, Naumann A, Runge R, Huebinger L, Kliewer A, Freudenberg R, Brogsitter C. Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy. Cancers 2022;14:2513. [DOI: 10.3390/cancers14102513] [Reference Citation Analysis]
2 Kokov KV, Egorova BV, German MN, Klabukov ID, Krasheninnikov ME, Larkin-Kondrov AA, Makoveeva KA, Ovchinnikov MV, Sidorova MV, Chuvilin DY. 212Pb: Production Approaches and Targeted Therapy Applications. Pharmaceutics 2022;14:189. [PMID: 35057083 DOI: 10.3390/pharmaceutics14010189] [Reference Citation Analysis]
3 Brandt F, Ullrich M, Laube M, Kopka K, Bachmann M, Löser R, Pietzsch J, Pietzsch HJ, van den Hoff J, Wodtke R. "Clickable" Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. J Med Chem 2021. [PMID: 34939412 DOI: 10.1021/acs.jmedchem.1c01791] [Reference Citation Analysis]
4 Barca C, Griessinger CM, Faust A, Depke D, Essler M, Windhorst AD, Devoogdt N, Brindle KM, Schäfers M, Zinnhardt B, Jacobs AH. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. Pharmaceuticals (Basel) 2021;15:13. [PMID: 35056071 DOI: 10.3390/ph15010013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Shao F, Long Y, Ji H, Jiang D, Lei P, Lan X. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics 2021;11:6800-17. [PMID: 34093854 DOI: 10.7150/thno.56989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Würnschimmel C, Wenzel M, Maurer T, Valdés Olmos RA, Vidal-Sicart S. Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. Q J Nucl Med Mol Imaging 2021;65:215-28. [PMID: 33829716 DOI: 10.23736/S1824-4785.21.03345-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Concilio SC, Russell SJ, Peng KW. A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy. Mol Ther Oncolytics 2021;21:98-109. [PMID: 33981826 DOI: 10.1016/j.omto.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Si Y, Guan J, Xu Y, Chen K, Kim S, Zhou L, Jaskula-Sztul R, Liu XM. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics 2020;12:E1079. [PMID: 33187322 DOI: 10.3390/pharmaceutics12111079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hennrich U, Benešová M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel) 2020;13:E38. [PMID: 32138377 DOI: 10.3390/ph13030038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
10 Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel) 2019;12:E114. [PMID: 31362406 DOI: 10.3390/ph12030114] [Cited by in Crossref: 65] [Cited by in F6Publishing: 84] [Article Influence: 21.7] [Reference Citation Analysis]
11 Leijon H, Remes S, Hagström J, Louhimo J, Mäenpää H, Schalin-Jäntti C, Miettinen M, Haglund C, Arola J. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol 2019;86:66-75. [PMID: 30529752 DOI: 10.1016/j.humpath.2018.11.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
12 Seith F, Schraml C, Reischl G, Nikolaou K, Pfannenberg C, la Fougère C, Schwenzer N. Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiol Med 2018;123:860-70. [PMID: 29961229 DOI: 10.1007/s11547-018-0917-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
13 Heidari P, Kunawudhi A, Martinez-Quintanilla J, Szretter A, Shah K, Mahmood U. Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics 2018;8:3380-91. [PMID: 29930736 DOI: 10.7150/thno.24017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget 2017;8:83128-41. [PMID: 29137329 DOI: 10.18632/oncotarget.20914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kalimuthu S, Jeong JH, Oh JM, Ahn BC. Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma. Int J Mol Sci 2017;18:E1639. [PMID: 28749424 DOI: 10.3390/ijms18081639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
17 Holmboe S, Hansen PL, Thisgaard H, Block I, Müller C, Langkjær N, Høilund-Carlsen PF, Olsen BB, Mollenhauer J. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411. PLoS One 2017;12:e0178286. [PMID: 28542563 DOI: 10.1371/journal.pone.0178286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
18 Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2016;18:7. [PMID: 26743514 DOI: 10.1007/s11912-015-0492-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
19 Mani BK, Zigman JM. A Strong Stomach for Somatostatin. Endocrinology 2015;156:3876-9. [PMID: 26474361 DOI: 10.1210/en.2015-1756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]